The bacterial species Clostridium difficile is often found in the gut of cystic fibrosis (CF) patients, but rarely makes them ill. In those instances, atypical symptoms can delay diagnosis and proper treatment, and may put patients’ lives in jeopardy, a case study of three people who nearly died of Clostridium difficile…
News
The emotional impact of an initial Pseudomonas aeruginosa (PA) respiratory infection on cystic fibrosis (CF) patients and those close to them is considerable, and it can lead them to adopt preventive measures that may be ineffectual and intrusive, researchers have found. For the study, “Perception of first respiratory infection…
Blood levels of a protein called sCD40L may serve as a biomarker to track lung complications in patients with cystic fibrosis (CF) infected by Pseudomonas aeruginosa bacteria, according to a new study. Results of the study were reported in the article “A High Level Of Soluble CD40L Is Associated With P. aeruginosa…
First Allied Securities has given the Cystic Fibrosis Foundation a $73,487 donation for research and programs dealing with the disease. Archie Manning, a retired National Football League quarterback, donated memorabilia that First Allied’s charity arm, First Philanthropy, auctioned for some of the donation. In the past seven years, First Philanthropy has…
Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery arm of the Cystic Fibrosis Foundation (CFF), has awarded Aridis Pharmaceuticals a grant to help develop Panaecin (gallium citrate), the company’s development-stage treatment for bacterial lung infections. Panaecin is being evaluated in a Phase 2a clinical trial (GALLIUM-IP-13, NCT02354859) in…
Mortality rates among cystic fibrosis (CF) patients in the United States have significantly decreased during the past decade, but hospitalizations and in-hospital deaths seem to be on the rise, according to the results of a new study. “Contemporary National Trends Of Cystic Fibrosis Hospitalizations And Co-Morbidities In The United States” was…
Hubrecht Organoid Technology (HUB) and the Dutch health insurance companies CZ, Zilveren Kruis and Menzis plan to launch a €3 million ($3.1 million) validation trial to determine whether HUB’s organoid technology can be used to assess how cystic fibrosis (CF) patients might respond to new therapies. HUB’s technology is based…
Catabasis Pharmaceuticals’ compound CAT-5571 showed promising effects on CFTR activity (the defective gene/protein in cystic fibrosis) in preclinical models of cystic fibrosis when added to treatment with the drug Orkambi. Whether these results also hold true in humans will soon be answered, as Catabasis plans to launch a Phase…
Protalix BioTherapeutics’ AIR DNase (alidornase alfa), developed to make mucus in the lungs of cystic fibrosis (CF) patients less sticky, showed remarkably good results in an early analysis of a small, proof-of-concept Phase 2 trial (NCT02722122). The inhaled drug is a DNase, an enzyme that works to chop…
Corbus Pharmaceuticals has completed its Phase 2 clinical trial evaluating Resunab (JBT-101) for the treatment of adults with cystic fibrosis (CF), and expects to soon report topline results. “We look forward to having our first safety data on JBT-101 in CF,” Barbara White, MD, chief medical officer at Corbus,…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.